FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:383-393 January 30, 2003 Number 5 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Solomon, C. G. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.

Methods The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin.

Results The mean age of the patients was 55.1 years, and the mean follow-up was 7.8 years. The decline in glycosylated hemoglobin values, systolic and diastolic blood pressure, serum cholesterol and triglyceride levels measured after an overnight fast, and urinary albumin excretion rate were all significantly greater in the intensive-therapy group than in the conventional-therapy group. Patients receiving intensive therapy also had a significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95 percent confidence interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79).

Conclusions A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.

Source Information

From the Steno Diabetes Center, Copenhagen (P.G., P.V., N.L., H.-H.P., O.P.); Herlev County Hospital, Herlev (N.L.); Amtssygehuset Roskilde, Roskilde (G.V.H.J.); and the Faculty of Health Science, Aarhus University, Aarhus (H.-H.P., O.P.) — all in Denmark.

Address reprint requests to Dr. Pedersen at the Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark, or at oluf{at}steno.dk.

Full Text of this Article

Related Letters:

Multifactorial Intervention and Cardiovascular Disease in Type 2 Diabetes
Ahmed S. A., Manning D., McGurk C., Bassan M. M., Gæde P., Parving H.-H., Pedersen O.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:1925-1927, May 8, 2003. Correspondence

This article has been cited by other articles:

• Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., Klein, R. (2009). Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. NEJM 361: 40-51 [Abstract] [Full Text]  
• Morath, C., Zeier, M. (2009). Transplantation in type 1 diabetes. Nephrol Dial Transplant 24: 2026-2029 [Full Text]  
• Shea, S., Weinstock, R. S., Teresi, J. A., Palmas, W., Starren, J., Cimino, J. J., Lai, A. M., Field, L., Morin, P. C., Goland, R., Izquierdo, R. E., Ebner, S., Silver, S., Petkova, E., Kong, J., Eimicke, J. P., IDEATel Consortium, (2009). A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. J. Am. Med. Inform. Assoc. 16: 446-456 [Abstract] [Full Text]  
• Hackam, D G, Sultan, N M, Criqui, M H (2009). Vascular protection in peripheral artery disease: systematic review and modelling study. Heart 95: 1098-1102 [Abstract] [Full Text]  
• Amarenco, P., Goldstein, L. B., Messig, M., O'Neill, B. J., Callahan, A. III, Sillesen, H., Hennerici, M. G., Zivin, J. A., Welch, K.M.A., on behalf of the SPARCL Investigators, (2009). Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke 40: 2486-2492 [Abstract] [Full Text]  
• Montori, V. M., Fernandez-Balsells, M. (2009). Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?. ANN INTERN MED 150: 803-808 [Abstract] [Full Text]  
• Chan, J. C., So, W.-Y., Yeung, C.-Y., Ko, G. T., Lau, I.-T., Tsang, M.-W., Lau, K.-P., Siu, S.-C., Li, J. K., Yeung, V. T., Leung, W. Y., Tong, P. C., for the SURE Study Group, (2009). Effects of Structured Versus Usual Care on Renal Endpoint in Type 2 Diabetes: The SURE Study: A randomized multicenter translational study. Diabetes Care 32: 977-982 [Abstract] [Full Text]  
• Marshall, S. M. (2009). Intensive Diabetes Management for High-Risk Patients: How Best to Deliver?. Diabetes Care 32: 1132-1133 [Full Text]  
• Cheng, A. Y.Y., Leiter, L. A. (2009). Cardiovascular risk and glycemic control. CMAJ 180: 907-908 [Full Text]  
• Riveline, J.-P., Teynie, J., Belmouaz, S., Franc, S., Dardari, D., Bauwens, M., Caudwell, V., Ragot, S., Bridoux, F., Charpentier, G., Marechaud, R., Hadjadj, S. (2009). Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 0: gfp181v1-gfp181 [Abstract] [Full Text]  
• Young, L. H., Wackers, F. J. Th., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., Ratner, R. E., Inzucchi, S. E., for the DIAD Investigators, (2009). Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes: The DIAD Study: A Randomized Controlled Trial. JAMA 301: 1547-1555 [Abstract] [Full Text]  
• Simmons, R. K., Coleman, R. L., Price, H. C., Holman, R. R., Khaw, K.-T., Wareham, N. J., Griffin, S. J. (2009). Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort. Diabetes Care 32: 708-713 [Abstract] [Full Text]  
• Halcox, J. P.J., Donald, A. E., Ellins, E., Witte, D. R., Shipley, M. J., Brunner, E. J., Marmot, M. G., Deanfield, J. E. (2009). Endothelial Function Predicts Progression of Carotid Intima-Media Thickness. Circulation 119: 1005-1012 [Abstract] [Full Text]  
• Adler, G. K., Bonyhay, I., Failing, H., Waring, E., Dotson, S., Freeman, R. (2009). Antecedent Hypoglycemia Impairs Autonomic Cardiovascular Function: Implications for Rigorous Glycemic Control. Diabetes 58: 360-366 [Abstract] [Full Text]  
• Soler, M. J., Ye, M., Wysocki, J., William, J., Lloveras, J., Batlle, D. (2009). Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am. J. Physiol. Renal Physiol. 296: F398-F405 [Abstract] [Full Text]  
• Bhattacharyya, O. K., Estey, E. A., Cheng, A. Y.Y. (2009). Update on the Canadian Diabetes Association 2008 clinical practice guidelines. cfp 55: 39-43 [Full Text]  
• Adams, H. P. Jr (2009). Secondary Prevention of Atherothrombotic Events After Ischemic Stroke. Mayo Clin Proc. 84: 43-51 [Abstract] [Full Text]  
• Panzetta, G., Basile, C., Santoro, A., Ancarani, E., Costantini, S., Guarnieri, F., Verzetti, G. (2008). Diabetics on dialysis in Italy: a nationwide epidemiological study. Nephrol Dial Transplant 23: 3988-3995 [Abstract] [Full Text]  
• Peterson, K. A., Radosevich, D. M., O'Connor, P. J., Nyman, J. A., Prineas, R. J., Smith, S. A., Arneson, T. J., Corbett, V. A., Weinhandl, J. C., Lange, C. J., Hannan, P. J. (2008). Improving Diabetes Care in Practice: Findings from the TRANSLATE trial. Diabetes Care 31: 2238-2243 [Abstract] [Full Text]  
• Anselmino, M., Wallander, M., Norhammar, A., Mellbin, L., Ryden, L. (2008). Implications of abnormal glucose metabolism in patients with coronary artery disease. Diabetes and Vascular Disease Research 5: 285-290 [Abstract]  
• Fruchart, J.-C., Sacks, F. M, Hermans, M. P, Assmann, G., Brown, W V., Ceska, R., Chapman, M J., Dodson, P. M, Fioretto, P., Ginsberg, H. N, Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R. S, Staels, B., Stock, J. K, Sy, R., Wanner, C., Zambon, A., Zimmet, P. (2008). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research 5: 319-335 [Abstract]  
• Schonauer, M., Thomas, A., Morbach, S., Niebauer, J., Schonauer, U., Thiele, H. (2008). Cardiac autonomic diabetic neuropathy. Diabetes and Vascular Disease Research 5: 336-344 [Abstract]  
• Bhattacharyya, O. K. MD PhD, Shah, B. R. MD PhD, Booth, G. L. MD MSc (2008). Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ 179: 920-926 [Full Text]  
• Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., Matthews, D. R. (2008). Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. NEJM 359: 1565-1576 [Abstract] [Full Text]  
• Maeda, S. (2008). Review: Genetics of diabetic nephropathy. Ther Adv Cardiovasc Dis 2: 363-371 [Abstract]  
• Chen, H.-S., Wu, T.-E., Jap, T.-S., Hsiao, L.-C., Lee, S.-H., Lin, H.-D. (2008). Beneficial Effects of Insulin on Glycemic Control and {beta}-Cell Function in Newly Diagnosed Type 2 Diabetes With Severe Hyperglycemia After Short-Term Intensive Insulin Therapy. Diabetes Care 31: 1927-1932 [Abstract] [Full Text]  
• Pommer, W. (2008). Prevalence of nephropathy in the German diabetes population--Is early referral to nephrological care a realistic demand today?. NDT Plus 1: iv2-iv5 [Abstract] [Full Text]  
• Grant, R. W., Wald, J. S., Schnipper, J. L., Gandhi, T. K., Poon, E. G., Orav, E. J., Williams, D. H., Volk, L. A., Middleton, B. (2008). Practice-Linked Online Personal Health Records for Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Arch Intern Med 168: 1776-1782 [Abstract] [Full Text]  
• Elkeles, R. S., Godsland, I. F., Feher, M. D., Rubens, M. B., Roughton, M., Nugara, F., Humphries, S. E., Richmond, W., Flather, M. D., for the PREDICT Study Group, (2008). Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J 29: 2244-2251 [Abstract] [Full Text]  
• Huelsmann, M., Neuhold, S., Strunk, G., Moertl, D., Berger, R., Prager, R., Abrahamian, H., Riedl, M., Pacher, R., Luger, A., Clodi, M. (2008). NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 29: 2259-2264 [Abstract] [Full Text]  
• Bailey, C. J, Day, C. (2008). Glycaemic memory. British Journal of Diabetes & Vascular Disease 8: 242-247 [Abstract]  
• Shah, B. R. (2008). Utilization of physician services for diabetic patients from ethnic minorities. J Public Health (Oxf) 30: 327-331 [Abstract] [Full Text]  
• Thiebaud, P., Demand, M., Wolf, S. A., Alipuria, L. L., Ye, Q., Gutierrez, P. R. (2008). Impact of Disease Management on Utilization and Adherence With Drugs and Tests: The case of diabetes treatment in the Florida: A Healthy State (FAHS) program. Diabetes Care 31: 1717-1722 [Abstract] [Full Text]  
• Wald, D. (2008). Commentary: Controversies in NICE guidance on familial hypercholesterolaemia. BMJ 337: a1304-a1304 [Full Text]  
• Kahn, R., Robertson, R. M., Smith, R., Eddy, D. (2008). The Impact of Prevention on Reducing the Burden of Cardiovascular Disease. Diabetes Care 31: 1686-1696 [Abstract] [Full Text]  
• Gaede, P., Valentine, W. J., Palmer, A. J., Tucker, D. M.D., Lammert, M., Parving, H.-H., Pedersen, O. (2008). Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes: Results and projections from the Steno-2 study. Diabetes Care 31: 1510-1515 [Abstract] [Full Text]  
• Kahn, R., Robertson, R. M., Smith, R., Eddy, D. (2008). The Impact of Prevention on Reducing the Burden of Cardiovascular Disease. Circulation 118: 576-585 [Abstract] [Full Text]  
• White, J. R. Jr (2008). Do People With Diabetes Need Statins?. The Diabetes Educator 34: 664-673 [Abstract] [Full Text]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• Denaro, C P, Mudge, A (2008). Should geriatric medicine remain a specialty? No. BMJ 337: a515-a515 [Full Text]  
• Dluhy, R. G., McMahon, G. T. (2008). Intensive Glycemic Control in the ACCORD and ADVANCE Trials. NEJM 358: 2630-2633 [Full Text]  
• Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., Hollenberg, N. K., the AVOID Study Investigators, (2008). Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. NEJM 358: 2433-2446 [Abstract] [Full Text]  
• Suying Li, , Jiannong Liu, , Gilbertson, D., McBean, M., Dowd, B., Collins, A. (2008). An Instrumental Variable Analysis of the Impact of Practice Guidelines on Improving Quality of Care and Diabetes-Related Outcomes in the Elderly Medicare Population. American Journal of Medical Quality 23: 222-230 [Abstract]  
• Karalliedde, J., Gnudi, L. (2008). ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant 23: 1796-1798 [Full Text]  
• Bloomgarden, Z. T. (2008). Cardiovascular Disease in Diabetes. Diabetes Care 31: 1260-1266 [Full Text]  
• Song, S.H., Hardisty, C.A. (2008). Diagnosing metabolic syndrome in type 2 diabetes: does it matter?. QJM 101: 487-491 [Abstract] [Full Text]  
• Astrup, A. S., Tarnow, L., Pietraszek, L., Schalkwijk, C. G., Stehouwer, C. D.A., Parving, H.-H., Rossing, P. (2008). Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years: Association with mortality and decline of glomerular filtration rate. Diabetes Care 31: 1170-1176 [Abstract] [Full Text]  
• Ruggenenti, P., Perticucci, E., Cravedi, P., Gambara, V., Costantini, M., Sharma, S. K., Perna, A., Remuzzi, G. (2008). Role of Remission Clinics in the Longitudinal Treatment of CKD. J. Am. Soc. Nephrol. 19: 1213-1224 [Full Text]  
• Rizza, R., Eddy, D., Kahn, R. (2008). Cure, Care, and Commitment: What Can We Look Forward To?. Diabetes Care 31: 1051-1059 [Full Text]  
• Koenig, W. (2008). Treating Residual Cardiovascular Risk: Will Lipoprotein-Associated Phospholipase A2 Inhibition Live Up to Its Promise?. J Am Coll Cardiol 51: 1642-1644 [Full Text]  
• Howard, B. V., Roman, M. J., Devereux, R. B., Fleg, J. L., Galloway, J. M., Henderson, J. A., Howard, Wm. J., Lee, E. T., Mete, M., Poolaw, B., Ratner, R. E., Russell, M., Silverman, A., Stylianou, M., Umans, J. G., Wang, W., Weir, M. R., Weissman, N. J., Wilson, C., Yeh, F., Zhu, J. (2008). Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. JAMA 299: 1678-1689 [Abstract] [Full Text]  
• Betteridge, D. J., DeFronzo, R. A., Chilton, R. J. (2008). PROactive: time for a critical appraisal. Eur Heart J 29: 969-983 [Abstract] [Full Text]  
• Palmer, A. J., Valentine, W. J., Chen, R., Mehin, N., Gabriel, S., Bregman, B., Rodby, R. A. (2008). A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 23: 1216-1223 [Abstract] [Full Text]  
• Hirsch, I. B. (2008). Piecing the Puzzle Together: ACCORDing to Whom?. J. Clin. Endocrinol. Metab. 93: 1161-1163 [Full Text]  
• Juutilainen, A., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M. (2008). Similarity of the Impact of Type 1 and Type 2 Diabetes on Cardiovascular Mortality in Middle-Aged Subjects. Diabetes Care 31: 714-719 [Abstract] [Full Text]  
• Yang, X., So, W. Y., Tong, P. C. Y., Ma, R. C. W., Kong, A. P. S., Lam, C. W. K., Ho, C. S., Cockram, C. S., Ko, G. T. C., Chow, C.-C., Wong, V. C. W., Chan, J. C. N. (2008). Development and Validation of an All-Cause Mortality Risk Score in Type 2 Diabetes: The Hong Kong Diabetes Registry. Arch Intern Med 168: 451-457 [Abstract] [Full Text]  
• Kelly, C. J., Booth, G. (2008). Pharmacist-led structured care for patients with diabetic nephropathy. British Journal of Diabetes & Vascular Disease 8: 86-88 [Abstract]  
• Bloomgarden, Z. T. (2008). Diabetic Neuropathy. Diabetes Care 31: 616-621 [Full Text]  
• Peter, R, Cox, A, Evans, M (2008). Management of diabetes in cardiovascular patients. Heart 94: 369-375 [Full Text]  
• Nesto, R. W., Mackie, K. (2008). Endocannabinoid system and its implications for obesity and cardiometabolic risk. Eur Heart J Suppl 10: B34-B41 [Abstract] [Full Text]  
• Gaede, P., Lund-Andersen, H., Parving, H.-H., Pedersen, O. (2008). Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. NEJM 358: 580-591 [Abstract] [Full Text]  
• Schmitz, O. (2008). The GLP-1 Concept in the Treatment of Type 2 Diabetes--Still Standing at the Gate of Dawn?. J. Clin. Endocrinol. Metab. 93: 375-377 [Full Text]  
• Standl, E., Schnell, O. (2008). Insulin as a First-Line Therapy in Type 2 Diabetes: Should the use of sulfonylureas be halted?. Diabetes Care 31: S136-S139 [Full Text]  
• Monnier, L., Colette, C. (2008). Glycemic Variability: Should we and can we prevent it?. Diabetes Care 31: S150-S154 [Abstract] [Full Text]  
• Milicevic, Z., Raz, I., Beattie, S. D., Campaigne, B. N., Sarwat, S., Gromniak, E., Kowalska, I., Galic, E., Tan, M., Hanefeld, M. (2008). Natural History of Cardiovascular Disease in Patients With Diabetes: Role of hyperglycemia. Diabetes Care 31: S155-S160 [Abstract] [Full Text]  
• Stirban, A. O., Tschoepe, D. (2008). Cardiovascular Complications in Diabetes: Targets and interventions. Diabetes Care 31: S215-S221 [Abstract] [Full Text]  
• Stirban, A. O., Tschoepe, D. (2008). Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?: Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?. Diabetes Care 31: S226-S228 [Abstract] [Full Text]  
• McManus, D. D., Ockene, I. S. (2008). Brief Supported Lifestyle Counseling: Modest Interventions Yield Modest Effects. Arch Intern Med 168: 129-130 [Full Text]  
• Christian, J. G., Bessesen, D. H., Byers, T. E., Christian, K. K., Goldstein, M. G., Bock, B. C. (2008). Clinic-Based Support to Help Overweight Patients With Type 2 Diabetes Increase Physical Activity and Lose Weight. Arch Intern Med 168: 141-146 [Abstract] [Full Text]  
• Anselmino, M., Ohrvik, J., Malmberg, K., Standl, E., Ryden, L., on behalf of the Euro Heart Survey Investigators, (2008). Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29: 177-184 [Abstract] [Full Text]  
• Peter, R., Rees, A. (2008). Review: Postprandial glycaemia and cardiovascular risk. British Journal of Diabetes & Vascular Disease 8: 8-14 [Abstract]  
• Fharm, E., Rolandsson, O., Weinehall, L. (2008). Guidelines improve general trend of lowered cholesterol levels in type 2 diabetes patients in spite of low adherence. Scand J Public Health 36: 69-75 [Abstract]  
• Covic, A., Gusbeth-Tatomir, P., Goldsmith, D. (2008). Negative outcome studies in end-stage renal disease: how dark are the storm clouds?. Nephrol Dial Transplant 23: 56-61 [Full Text]  
• Yee, J. (2008). Diabetic Kidney Disease: Chronic Kidney Disease and Diabetes. Diabetes Spectr. 21: 8-10 [Full Text]  
• Steigerwalt, S. (2008). Management of Hypertension in Diabetic Patients With Chronic Kidney Disease. Diabetes Spectr. 21: 30-36 [Abstract] [Full Text]  
• Flack, J. M., Victor, R., Watson, K., Ferdinand, K. C., Saunders, E., Tarasenko, L., Jamieson, M. J., Shi, H., Bruschi, P. (2008). Improved Attainment of Blood Pressure and Cholesterol Goals Using Single-Pill Amlodipine/Atorvastatin in African Americans: The CAPABLE Trial. Mayo Clin Proc. 83: 35-45 [Abstract] [Full Text]  
• (2007). New data from the FIELD study: protecting the diabetic eye. Diabetes and Vascular Disease Research 4: S1-S7  
• Kapur, A., De Palma, R. (2007). Mortality after myocardial infarction in patients with diabetes mellitus. Heart 93: 1504-1506 [Abstract] [Full Text]  
• Preston, R. A., Harvey, P., Herfert, O., Dykstra, G., Jukema, J. W., Sun, F., Gillen, D. (2007). A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial. J Clin Pharmacol 47: 1555-1569 [Abstract] [Full Text]  
• Kloos, C., Samann, A., Lehmann, T., Braun, A., Heckmann, B., Muller, U. A. (2007). Flexible Intensive Versus Conventional Insulin Therapy in Insulin-Naive Adults With Type 2 Diabetes: An open-label, randomized, controlled, crossover clinical trial of metabolic control and patient preference. Diabetes Care 30: 3031-3032 [Full Text]  
• Air, E. L., Kissela, B. M. (2007). Diabetes, the Metabolic Syndrome, and Ischemic Stroke: Epidemiology and possible mechanisms. Diabetes Care 30: 3131-3140 [Full Text]  
• Greiver, M. (2007). Improving diabetes care in my practice. cfp 53: 1897-1897 [Full Text]  
• Daly, C A, Hildebrandt, P, Bertrand, M, Ferrari, R, Remme, W, Simoons, M, Fox, K M, on behalf of the EUROPA investigators, (2007). Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 93: 1406-1411 [Abstract] [Full Text]